Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03399084 · ClinicalTrials.gov registry record · Phase 1
A Study Comparing Two Ferric Carboxymaltose Formulations in Patients With Iron Deficiency Anemia
A Phase 1 study of Iron Deficiency Anemia, sponsored by Sandoz.
- Completed
- Registry status
- Phase 1
- Development phase
- 71
- Enrollment target
- 1
- Study location
NCT03399084: Completed Phase 1 study of Iron Deficiency Anemia, sponsored by Sandoz.
NCT03399084 is a Phase 1 study of Iron Deficiency Anemia that has completed, run by Sandoz. The registered enrollment target is 71 participants, below the 191-participant average among 24 other Iron Deficiency Anemia trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03399084, a Phase 1 study of Iron Deficiency Anemia, has completed, sponsored by Sandoz.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 71 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate bioequivalence of two formulations of Ferric Carboxymaltose as measured by serum total iron, in adult patients with iron deficiency anemia.
Primary Outcome
Measured by Cmax - The maximum plasma concentration of iron
Conditions Studied
Interventions
- DRUG Ferric carboxymaltose
Study Locations (1)
Florida
- Sandoz Investigative Site - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2017-11-29 |
| Est. Completion | 2019-01-15 |
| Phase | Phase 1 |
What the finished NCT03399084 record still lists
NCT03399084 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 71 participants, a relatively small participant target, below the 191-participant average among 24 other Iron Deficiency Anemia trials with a reported enrollment target (63% lower).
The record links to 1 condition, with Iron Deficiency Anemia appearing as the primary indexed condition, and to 1 intervention - of which Ferric carboxymaltose is the first listed.
NCT03399084 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT03399084 about?
NCT03399084 is a clinical study titled "A Study Comparing Two Ferric Carboxymaltose Formulations in Patients With Iron Deficiency Anemia". This study will evaluate bioequivalence of two formulations of Ferric Carboxymaltose as measured by serum total iron, in adult patients with iron deficiency anemia.
What is the current status of trial NCT03399084?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 71 participants. The study started on 2017-11-29. Estimated completion is 2019-01-15.
What conditions does trial NCT03399084 study?
This clinical trial studies the following conditions: Iron Deficiency Anemia.
What interventions are being tested in trial NCT03399084?
The interventions under investigation include: Ferric carboxymaltose (DRUG).
Who is sponsoring clinical trial NCT03399084?
This trial is sponsored by Sandoz, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03399084 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Iron Deficiency Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03399084's enrollment target sits among peer trials
71 16th of 24 higher than 9 of 24 other Iron Deficiency Anemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Iron Deficiency Anemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants
RECRUITING · Phase 2
-
Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
RECRUITING · Phase 3
-
A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects
RECRUITING · Phase 3
-
Iron Deficiency Anemia (IDA) and the Brain
RECRUITING · Phase 4
-
Intravenous Versus Oral Iron for Treating Iron-Deficiency Anemia in Pregnancy
RECRUITING · Phase 3
-
An Extension Trial to Assess the Safety of Re-dosing of Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05452889 · 71 participants · Early Phase 1
PET Image in PAH Patients
- NCT05766943 · 71 participants · NA
Reduction of Myopotential Interference With Smart Pass in S-ICD Patients
- NCT06229678 · 71 participants · Early Phase 1
Ketones, SGLT2, HFrEF
- NCT06377566 · 71 participants · Phase 2
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI